Ken Griffin Dynavax Technologies Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$10.05 - $11.61 $65,325 - $75,465	-6,500 Reduced 41.94%	9,000 $100,000
Q2 2024 Aug 14, 2024	SELL	$10.73 - $12.58 $1.09 Million - $1.27 Million	-101,300 Reduced 86.73%	15,500 $174,000
Q1 2024 May 15, 2024	BUY	$11.7 - $14.98 $1.18 Million - $1.51 Million	100,900 Added 634.59%	116,800 $1.45 Million
Q4 2023 Feb 14, 2024	SELL	$13.09 - $14.98 $183,260 - $209,720	-14,000 Reduced 46.82%	15,900 $222,000
Q3 2023 Nov 14, 2023	BUY	$12.64 - $14.99 $97,328 - $115,423	7,700 Added 34.68%	29,900 $441,000
Q2 2023 Aug 14, 2023	SELL	$9.85 - $13.17 $25,610 - $34,242	-2,600 Reduced 10.48%	22,200 $286,000
Q1 2023 May 15, 2023	SELL	$9.44 - $11.88 $1.11 Million - $1.39 Million	-117,200 Reduced 82.54%	24,800 $243,000
Q4 2022 Feb 14, 2023	SELL	$10.27 - $13.29 $149,942 - $194,034	-14,600 Reduced 9.32%	142,000 $1.51 Million
Q3 2022 Nov 14, 2022	BUY	$9.93 - $17.44 $164,838 - $289,504	16,600 Added 11.86%	156,600 $1.64 Million

273

130M

451K

203K

Ticker DVAX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 126,474,000
Market Cap $1.54B
Description
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.